The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders.

Trial Profile

The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Flutemetamol-F-18 (Primary) ; RO 6958948 (Primary)
  • Indications Cognition disorders; Neurodegenerative disorders
  • Focus Diagnostic use; Therapeutic Use
  • Acronyms BioFINDER2
  • Most Recent Events

    • 09 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top